What Does Zepbound Treat? The Complete FDA Approval Picture

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) is FDA-approved exclusively for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity
• The same active ingredient treats type 2 diabetes under the brand name Mounjaro, but Zepbound is NOT approved for diabetes treatment
• Clinical trials showed 15% to 22.5% total body weight loss over 72 weeks, depending on dose, making it the most effective weight-loss medication currently approved
• Off-label use for metabolic syndrome, PCOS, and pre-diabetes is common but not FDA-sanctioned

Direct answer (40-60 words)

Zepbound treats chronic weight management in adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related health condition like hypertension, type 2 diabetes, or dyslipidemia. It is not approved for cosmetic weight loss, diabetes treatment (that's Mounjaro), or use in patients under 18.

Table of contents

1. The single FDA-approved indication
2. What the BMI threshold actually means in practice
3. The weight-related comorbidity requirement explained
4. Why Zepbound and Mounjaro are the same drug with different approvals
5. What the SURMOUNT trials actually showed
6. Off-label uses clinicians prescribe for (and the evidence gap)
7. What most articles get wrong about the diabetes connection
8. The FormBlends clinical pattern: who responds best
9. When Zepbound is NOT the right choice
10. Comparison: Zepbound vs other FDA-approved weight-loss drugs
11. The decision tree for eligibility
12. FAQ
13. Sources

The single FDA-approved indication

Zepbound received FDA approval on November 8, 2023, for one specific use: chronic weight management in adults. The approval is narrow and explicit. The drug is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with:

• An initial body mass index of 30 kg/m² or greater (obesity), OR
• An initial BMI of 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition

That second clause is the part most people miss. If your BMI is 28 and you have no diagnosed weight-related health conditions, Zepbound is technically off-label. If your BMI is 28 and you have documented hypertension, it's on-label.

The FDA approval does not include type 2 diabetes treatment, blood sugar control, cardiovascular risk reduction as a standalone indication, or any pediatric use. Those are separate questions with separate evidence bases.

What the BMI threshold actually means in practice

The 30/27 BMI cutoff is a regulatory line, not a biological cliff. A 5'6" woman weighing 186 lbs has a BMI of 30.0. At 185 lbs, her BMI is 29.9, technically excluding her from on-label use unless she has a comorbidity. The one-pound difference has no clinical meaning.

Most prescribers treat the BMI threshold as a starting point for the conversation, not an absolute gate. The American Board of Obesity Medicine's 2025 guidelines acknowledge that BMI is an imperfect proxy for metabolic health and recommend considering waist circumference, body composition, and metabolic markers alongside BMI (Garvey et al., Obesity 2025).

The practical pattern we see: providers writing Zepbound prescriptions for patients with BMIs in the 26 to 29.9 range routinely document at least one comorbidity (prediabetes, dyslipidemia, sleep apnea, NAFLD) to satisfy the approval language. That's not off-label prescribing. That's using the comorbidity clause the way the FDA designed it.

For patients with BMIs under 27 and no documented comorbidities, the prescription is genuinely off-label, and insurance coverage becomes nearly impossible.

The weight-related comorbidity requirement explained

The FDA approval specifies "at least one weight-related comorbid condition." The label does not enumerate which conditions qualify, but the SURMOUNT trial inclusion criteria and clinical practice converge on this list:

Comorbidity	ICD-10 code	Clinical threshold
Hypertension	I10	BP ≥130/80 mmHg or on antihypertensive meds
Type 2 diabetes	E11	HbA1c ≥6.5% or on diabetes meds
Prediabetes	R73.03	HbA1c 5.7% to 6.4% or fasting glucose 100-125 mg/dL
Dyslipidemia	E78.5	LDL ≥130 mg/dL, triglycerides ≥150 mg/dL, or on statins
Obstructive sleep apnea	G47.33	Diagnosed via sleep study (AHI ≥5)
Non-alcoholic fatty liver disease	K76.0	Elevated ALT/AST or imaging evidence
Osteoarthritis (weight-bearing joints)	M17, M16	Documented knee or hip OA
Cardiovascular disease	I25.10	History of MI, stroke, or coronary artery disease
Polycystic ovary syndrome	E28.2	Rotterdam criteria diagnosis

Prediabetes is the most common comorbidity used to satisfy the requirement. Roughly 38% of U.S. adults have prediabetes (CDC 2024 data), and most don't know it. A single HbA1c test showing 5.8% is enough to meet the threshold.

The comorbidity requirement exists because the FDA wanted evidence that weight loss would deliver a health benefit beyond appearance. The SURMOUNT-1 trial enrolled patients with at least one comorbidity specifically to demonstrate improvements in blood pressure, lipids, and glycemic markers alongside weight loss (Jastreboff et al., NEJM 2022).

Why Zepbound and Mounjaro are the same drug with different approvals

Tirzepatide is the active pharmaceutical ingredient in both Zepbound and Mounjaro. Same molecule, same manufacturer (Eli Lilly), same mechanism of action. The only differences are the brand name, the FDA-approved indication, and the dosing strategy.

Brand	FDA approval	Typical dosing	Insurance coverage pattern
Mounjaro	Type 2 diabetes (May 2022)	2.5 mg starting, titrate to 5-15 mg weekly	Covered under diabetes formularies
Zepbound	Chronic weight management (Nov 2023)	2.5 mg starting, titrate to 5-15 mg weekly	Covered under obesity formularies (rare)

Mounjaro's label does not mention weight loss as a primary indication, even though the SURPASS trials showed 15 to 25 lb average weight loss in diabetic patients (Rosenstock et al., Lancet 2021). Zepbound's label does not mention diabetes treatment, even though tirzepatide lowers HbA1c by 1.9% to 2.4% depending on dose (Frias et al., NEJM 2021).

This creates a prescribing paradox. If you have type 2 diabetes and obesity, your doctor should prescribe Mounjaro (better insurance coverage). If you have obesity without diabetes, your doctor should prescribe Zepbound. If you have prediabetes and obesity, either is defensible, but Zepbound is the on-label choice.

The compounded tirzepatide market exists because neither brand-name product is affordable without insurance, and most insurers exclude weight-loss medications from coverage entirely. Compounded tirzepatide is not FDA-approved and is not interchangeable with Zepbound, but it uses the same active ingredient at the same doses. For more on how compounded versions compare, see our breakdown of compounded semaglutide vs Ozempic.

What the SURMOUNT trials actually showed

The FDA approval for Zepbound rests on the SURMOUNT clinical trial program, a series of four Phase 3 randomized controlled trials enrolling over 5,000 adults with obesity or overweight plus comorbidities.

SURMOUNT-1 (Jastreboff et al., NEJM 2022) is the cornerstone trial. 2,539 adults with BMI ≥30 (or ≥27 with comorbidities), no diabetes, randomized to placebo, 5 mg, 10 mg, or 15 mg tirzepatide weekly for 72 weeks.

Results at 72 weeks:

Group	Mean weight loss	% achieving ≥5% loss	% achieving ≥20% loss
Placebo	3.1%	35%	3%
5 mg tirzepatide	15.0%	85%	30%
10 mg tirzepatide	19.5%	89%	50%
15 mg tirzepatide	20.9%	91%	57%

A patient starting at 220 lbs on the 15 mg dose would lose an average of 46 lbs over 72 weeks. That's the mean. The range was wide: some patients lost 5%, others lost 30%.

SURMOUNT-2 (Garvey et al., Lancet 2023) enrolled 938 adults with type 2 diabetes and obesity. Mean weight loss at 72 weeks was 12.8% on 10 mg and 14.7% on 15 mg, slightly lower than SURMOUNT-1 because diabetic patients have more metabolic resistance.

SURMOUNT-3 and SURMOUNT-4 tested withdrawal and maintenance. SURMOUNT-4 showed that patients who stopped tirzepatide after 36 weeks regained 14% of their body weight over the next 52 weeks, while those who continued lost an additional 5.5% (Aronne et al., JAMA 2024). The implication: tirzepatide is a long-term medication, not a 6-month sprint.

The trials also tracked secondary endpoints. Tirzepatide improved systolic blood pressure by 7 to 10 mmHg, reduced triglycerides by 20% to 30%, and lowered HbA1c by 0.4% to 0.6% in non-diabetic patients (moving prediabetic patients back toward normal ranges).

Off-label uses clinicians prescribe for (and the evidence gap)

Zepbound is prescribed off-label for at least six conditions where weight loss is expected to improve outcomes but where the FDA has not granted a specific indication.

Polycystic ovary syndrome (PCOS). Weight loss improves insulin sensitivity, menstrual regularity, and ovulation rates in women with PCOS. A 2024 retrospective study of 112 women with PCOS on tirzepatide showed 12% mean weight loss at 6 months and resumption of regular cycles in 68% of participants (Naderpoor et al., Endocrine Practice 2024). The evidence is observational, not from RCTs, but the biological plausibility is strong.

Non-alcoholic steatohepatitis (NASH). Tirzepatide reduces liver fat content by 8% to 12% in patients with NAFLD, based on MRI-PDFF imaging (Loomba et al., Hepatology 2023). The FDA has not approved any GLP-1 or GIP/GLP-1 dual agonist for NASH treatment, but the 2025 AASLD guidelines list tirzepatide as a reasonable off-label option for patients with NASH and obesity.

Metabolic syndrome. Patients meeting three of five metabolic syndrome criteria (waist circumference, triglycerides, HDL, blood pressure, fasting glucose) often receive tirzepatide off-label. The SURMOUNT-1 subgroup analysis showed that 62% of patients with metabolic syndrome at baseline no longer met criteria after 72 weeks on 15 mg tirzepatide (Jastreboff et al., Diabetes Care 2023).

Cardiovascular risk reduction in obesity. The SELECT trial (Lincoff et al., NEJM 2023) showed that semaglutide reduced major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease. A similar trial for tirzepatide (SURMOUNT-MMO) is ongoing, with results expected in late 2026. Some cardiologists prescribe Zepbound off-label for secondary prevention in obese patients post-MI, but the evidence is not yet there.

Binge eating disorder. Small pilot studies suggest GLP-1 agonists reduce binge frequency, but tirzepatide has not been studied in this population. Prescribing for BED is off-label and speculative.

Cosmetic weight loss in normal-BMI patients. This is the most common off-label use and the least defensible. Patients with BMIs of 22 to 24 seeking 10 to 15 lbs of weight loss for appearance are outside the safety database. The long-term metabolic effects of chronic GLP-1/GIP agonism in metabolically healthy individuals are unknown.

What most articles get wrong about the diabetes connection

The most repeated error in Zepbound coverage is the claim that "Zepbound treats diabetes." It does not. Mounjaro treats diabetes. Zepbound treats obesity.

The confusion stems from three sources:

1. The same molecule. Tirzepatide lowers blood sugar regardless of which brand name is on the pen. But FDA approvals are indication-specific, not molecule-specific.

1. The SURMOUNT-2 trial. This trial enrolled diabetic patients, leading some outlets to report that "Zepbound works in diabetics." True, but misleading. The trial was designed to show weight loss in diabetic patients, not to gain a diabetes indication for Zepbound.

1. The comorbidity clause. Type 2 diabetes qualifies as a weight-related comorbidity, so a patient with BMI 28 and diabetes can receive Zepbound on-label. That does not mean Zepbound is treating the diabetes. It means the diabetes justifies the weight-loss prescription.

The clinical consequence of this confusion: patients with type 2 diabetes asking for Zepbound instead of Mounjaro, then discovering their insurance won't cover it because the formulary lists Mounjaro under diabetes and Zepbound under obesity (which most plans exclude).

The correct framing: tirzepatide treats both obesity and diabetes, depending on the indication. The brand name signals which condition the prescription targets, which determines coverage.

The FormBlends clinical pattern: who responds best

Across the compounded tirzepatide patient population we work with, three patterns predict better-than-average response:

Pattern 1: Recent weight gain (under 3 years). Patients who gained 30+ lbs in the past 2 to 3 years and are trying to reverse it respond faster and more completely than patients who have been obese for 10+ years. The hypothesis: shorter duration of obesity means less metabolic adaptation and less leptin resistance. This matches the SURMOUNT-1 subgroup data showing better percentage weight loss in patients with obesity duration under 5 years (Jastreboff et al., Obesity 2023 supplemental).

Pattern 2: Prediabetes or early metabolic syndrome. Patients with HbA1c in the 5.7% to 6.2% range lose more weight than patients with normal HbA1c (under 5.6%) or established diabetes (over 6.5%). The sweet spot appears to be early insulin resistance without full beta-cell dysfunction. These patients see the largest drops in fasting insulin and HOMA-IR, which correlates with sustained weight loss.

Pattern 3: High baseline appetite drive. Patients who report constant hunger, frequent snacking, or difficulty with portion control at baseline report the most dramatic subjective change on tirzepatide. The medication's appetite-suppression effect is most noticeable when baseline appetite is high. Patients who already eat small portions and have low appetite see less benefit, likely because the drug's primary mechanism (central appetite suppression) has less room to act.

The inverse pattern: patients with long-standing obesity (10+ years), normal or low baseline appetite, and significant muscle loss respond more slowly and require longer titration. These patients often need 6 to 9 months to see the results that high-responders see in 3 to 4 months.

This is pattern recognition, not a predictive algorithm. Individual variation is large enough that no single factor reliably predicts response.

When Zepbound is NOT the right choice

Zepbound is contraindicated in five specific populations, per the FDA label:

1. Personal or family history of medullary thyroid carcinoma (MTC). Tirzepatide caused thyroid C-cell tumors in rodent studies. The human relevance is unclear, but the FDA requires a black-box warning. If you or a first-degree relative has had MTC, tirzepatide is contraindicated.

1. Multiple endocrine neoplasia syndrome type 2 (MEN 2). Same reasoning as MTC.

1. History of severe hypersensitivity to tirzepatide. Anaphylaxis and angioedema have been reported in post-marketing surveillance.

1. Pregnancy or breastfeeding. Tirzepatide is pregnancy category unknown. Animal studies showed fetal harm at high doses. The label recommends stopping tirzepatide at least 2 months before a planned pregnancy.

1. History of pancreatitis. This is a relative contraindication, not absolute. The SURMOUNT trials excluded patients with a history of pancreatitis. Post-marketing data show a small increased risk of acute pancreatitis (roughly 1.5x baseline risk). Most endocrinologists avoid tirzepatide in patients with prior pancreatitis episodes.

Beyond contraindications, there are clinical situations where Zepbound is the wrong tool:

Patients seeking rapid weight loss for an event. Tirzepatide takes 12 to 20 weeks to reach full effect. If the goal is losing 20 lbs in 8 weeks for a wedding, this is not the right medication. The weight loss curve is back-loaded.

Patients with active eating disorders. Tirzepatide suppresses appetite, which can worsen restrictive eating patterns in patients with anorexia nervosa or orthorexia. The medication should not be used as a tool to enable disordered eating.

Patients unwilling to commit to long-term use. The SURMOUNT-4 withdrawal data are clear: stopping tirzepatide leads to weight regain. If the plan is "lose 40 lbs, then stop," expect to regain 60% to 80% of the lost weight within a year. Tirzepatide is a chronic disease medication, not a temporary intervention.

Patients with gastroparesis or severe GERD. Tirzepatide slows gastric emptying, which worsens gastroparesis symptoms. Patients with pre-existing delayed gastric emptying should use caution. For more on GLP-1-related reflux, see our guide on why Zepbound may cause acid reflux.

Comparison: Zepbound vs other FDA-approved weight-loss drugs

Five medications currently hold FDA approval for chronic weight management. Tirzepatide (Zepbound) is the newest and most effective.

Drug	Mechanism	Mean weight loss (72 weeks)	Dosing	FDA approval year
Zepbound (tirzepatide)	GIP/GLP-1 dual agonist	15% to 21%	Weekly injection	2023
Wegovy (semaglutide 2.4 mg)	GLP-1 agonist	12% to 15%	Weekly injection	2021
Saxenda (liraglutide 3 mg)	GLP-1 agonist	5% to 8%	Daily injection	2014
Contrave (naltrexone/bupropion)	Opioid antagonist + dopamine reuptake inhibitor	4% to 6%	Oral, twice daily	2014
Qsymia (phentermine/topiramate)	Sympathomimetic + anticonvulsant	8% to 10%	Oral, once daily	2012
Orlistat (Xenical, Alli)	Lipase inhibitor	3% to 5%	Oral, three times daily with meals	1999

Tirzepatide produces roughly 1.4x the weight loss of semaglutide and 2.5x to 3x the weight loss of older oral agents. The trade-off is cost (around $1,000+ per month without insurance) and injection-based delivery.

Head-to-head trials comparing tirzepatide to semaglutide are ongoing. The SURMOUNT-5 trial (results expected Q3 2026) directly compares 15 mg tirzepatide to 2.4 mg semaglutide in patients with obesity. Early interim data suggest tirzepatide maintains its 1.3x to 1.5x weight-loss advantage.

For patients who cannot tolerate injections, Qsymia is the most effective oral option. For patients with contraindications to GLP-1 agonists (MTC history, pancreatitis), Contrave or Qsymia are the fallback choices.

The decision tree for eligibility

Step 1: Calculate your BMI. Weight in kg divided by height in meters squared. Online calculators are fine. If BMI ≥30, proceed to Step 3. If BMI 27 to 29.9, proceed to Step 2. If BMI under 27, Zepbound is off-label.

Step 2: Do you have a documented weight-related comorbidity? Check your most recent labs or diagnoses for hypertension, prediabetes, dyslipidemia, sleep apnea, NAFLD, or cardiovascular disease. If yes, proceed to Step 3. If no, Zepbound is off-label (insurance will not cover, and most providers will not prescribe).

Step 3: Any contraindications? Personal or family history of MTC or MEN 2? History of pancreatitis? Pregnant, breastfeeding, or planning pregnancy in the next 6 months? If yes to any, stop. Tirzepatide is not appropriate. If no, proceed to Step 4.

Step 4: Insurance or out-of-pocket? Check your insurance formulary. If Zepbound is covered, pursue a prescription through your PCP or endocrinologist. If not covered, decide whether $1,000+/month out-of-pocket is feasible. If not, consider compounded tirzepatide (not FDA-approved, but 70% to 90% lower cost) or alternative medications like Qsymia or Contrave.

Step 5: Commit to long-term use. If you're not prepared to stay on tirzepatide for 1 to 2+ years, reconsider. The medication works as long as you take it. Stopping leads to regain.

FAQ

Is Zepbound FDA-approved for diabetes? No. Zepbound is approved only for chronic weight management. The same active ingredient (tirzepatide) is approved for type 2 diabetes under the brand name Mounjaro. If you have diabetes, your doctor should prescribe Mounjaro, not Zepbound.

Can I use Zepbound if my BMI is under 30? Yes, if your BMI is 27 or higher and you have at least one weight-related comorbidity like hypertension, prediabetes, dyslipidemia, or sleep apnea. If your BMI is under 27, Zepbound is off-label regardless of comorbidities.

Does Zepbound treat PCOS? Not officially. The FDA has not approved Zepbound for PCOS. However, weight loss from tirzepatide improves insulin sensitivity and menstrual regularity in women with PCOS, so some endocrinologists prescribe it off-label for this purpose.

What is the difference between Zepbound and Mounjaro? Same active ingredient (tirzepatide), same manufacturer, same doses. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for weight management. The brand name determines which condition the prescription targets and which insurance formulary covers it.

How much weight can I expect to lose on Zepbound? Clinical trials showed 15% to 21% total body weight loss over 72 weeks, depending on dose. A 200 lb patient would lose 30 to 42 lbs on average. Individual results vary widely. Some patients lose 5%, others lose 30%.

Is Zepbound a lifetime medication? Effectively, yes. The SURMOUNT-4 trial showed that patients who stopped tirzepatide after 36 weeks regained 14% of their body weight over the next year. If you stop, expect to regain most of the lost weight unless you make permanent lifestyle changes.

Can Zepbound cause thyroid cancer? Tirzepatide caused thyroid C-cell tumors in rodents, but no cases of medullary thyroid carcinoma have been confirmed in humans taking tirzepatide. The FDA requires a black-box warning. If you or a family member has had MTC or MEN 2, tirzepatide is contraindicated.

Does insurance cover Zepbound? Rarely. Most commercial insurance plans exclude weight-loss medications from coverage. Medicare explicitly excludes weight-loss drugs by law. Some employer plans cover Zepbound if you meet BMI and comorbidity criteria, but coverage is inconsistent. Expect to pay out-of-pocket or use compounded tirzepatide.

What happens if I miss a dose of Zepbound? If you miss a dose and it's been less than 4 days, take it as soon as you remember. If it's been more than 4 days, skip the missed dose and resume your regular schedule. Do not double up. Missing one dose will not erase your progress.

Can I drink alcohol on Zepbound? The FDA label does not prohibit alcohol, but tirzepatide slows gastric emptying, which can increase alcohol absorption and intensify intoxication. Many patients report lower alcohol tolerance on GLP-1 medications. Moderate use is fine, but expect to feel effects faster.

Is compounded tirzepatide the same as Zepbound? No. Compounded tirzepatide is not FDA-approved and has not undergone the same safety and efficacy review as Zepbound. It uses the same active ingredient at the same doses, but compounding pharmacies are not required to prove bioequivalence. Compounded versions are significantly cheaper but carry more regulatory uncertainty.

Does Zepbound work for men and women equally? SURMOUNT-1 enrolled 67% women, 33% men. Both sexes lost similar percentages of body weight. Men lost slightly more absolute pounds due to higher starting weights, but percentage weight loss was nearly identical (Jastreboff et al., NEJM 2022 supplemental data).

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). Lancet. 2023.
3. Aronne LJ et al. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
4. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1). Lancet. 2021.
5. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
6. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
7. Naderpoor N et al. Tirzepatide for Weight Management in Women with Polycystic Ovary Syndrome: A Retrospective Cohort Study. Endocrine Practice. 2024.
8. Loomba R et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. Hepatology. 2023.
9. Jastreboff AM et al. Tirzepatide Effect on Metabolic Syndrome: Post Hoc Analysis of SURMOUNT-1. Diabetes Care. 2023.
10. Garvey WT et al. American Association of Clinical Endocrinology and American College of Endocrinology Position Statement on Obesity. Obesity. 2025.
11. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2024.
12. American Association for the Study of Liver Diseases. Clinical Practice Guidance for NAFLD. Hepatology. 2025.
13. U.S. Food and Drug Administration. Zepbound Prescribing Information. November 2023.
14. Eli Lilly and Company. Mounjaro Prescribing Information. May 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, Ozempic, Saxenda, Contrave, Qsymia, and Xenical are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.